Abstract 4973
Background
Malignant bowel obstruction can occur in 18% of cases. SEMS can be an alternative to surgery. BV has been associated with bowel perforation but data on the safety of SEMS for occlusive colon cancer during BV-containing regimens are lacking.
Methods
Retrospective analysis of 136 patients with malignant bowel obstruction who underwent placement of SEMS between 2012 and 2017 in two hospitals. Chemotherapy and BV-containing regimens, stent-related complications and outcomes were recorded.
Results
58 (42.6%) SEMS were placed as a bridge to surgery and 78 (57.4%) as a palliative intent for stage IV disease. 129 patients (94.9%) had a left-sided obstruction. Technical success was achieved in 133 of 136 (98%). Overall, major stent-related complications after two-weeks of insertion were observed in 36 patients (26.5%): Re-obstruction in 18 patients (50%), 11 perforations (30.5%), 5 bleeding (14%) and 2 migrations (5.5%). Complications in the metastatic group (n = 78) 14 (18%) had re-obstructions, 7 (9%) perforations, 4 (5%) minor bleeding and 2 (2.5%) migrations. Multivariate analysis identified stage IV and chemotherapy as significant risk factors for stent-related complications. Patients who received systemic therapy are more likely to develop complications (OR 1.84; CI95% 1.29-6.22, p = 0.0007). 16 patients received BV, 2 (12.5%) had a perforation. Univariate analysis did not show that BV was more likely to develop perforations, although the incidence was higher in this subset of patients. No differences were observed between chemotherapy alone and BV in overall complications. Kaplan-Meier analysis showed significant longer OS for patients treated with systemic therapy (27 vs. 11 months, p = <0.00001). There is a significant benefit of BV compared to chemotherapy alone (43 vs. 39 months, p = 0.02).
Conclusions
Placement of SEMS is effective and relatively safe but, with an overall complication rate of 26%. The major early risk is perforation that can increase up to 12% during BV treatment. In patients with obstructing advanced colorectal cancer that would benefit from SEMS, we should consider the risks associated with systemic therapies, taking into account the improvement in survival with BV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract